Zydus Lifesciences Limited received final approval from the US Food and Drug Administration (USFDA) for its Estradiol and Levonorgestrel Transdermal System, with expected annual sales of $45.7 million in the US market.

Approval details

The approval covers the Estradiol and Levonorgestrel Transdermal System, a patch-based drug delivery product indicated for treating moderate to severe symptoms of menopause and preventing osteoporosis in postmenopausal women. The product corresponds to the reference listed drug Climara Pro® Transdermal System.

Zydus Lifesciences is also eligible for 180-day CGT (Competitive Generic Therapy) exclusivity in connection with this approval. This designation provides a period of market exclusivity for the generic product in the US, subject to provisions of the U.S. Federal Food, Drug, and Cosmetic Act. The exclusivity period commences upon first commercial marketing of the product.

Manufacturing and portfolio context

The product will be manufactured at the group's facility in Moraiya, near Ahmedabad, Gujarat. As of September 30, 2026, Zydus Lifesciences holds 458 approvals from the USFDA and has filed 516 ANDAs with the agency.

Key highlights

The following table summarises the key details of the USFDA approval:

• The product is a transdermal (patch) delivery system combining Estradiol and Levonorgestrel.
• The 180-day CGT exclusivity designation is granted by the USFDA for certain generic drugs that face limited competition.
• The expected annual sales figure of $45.7 million pertains to the US market, based on IQVIA MAT Aug-2026 data.

Zydus Lifesciences received 5 observations from the US Food and Drug Administration following an inspection at its Moraiya plant. The company has stated plans to resolve the issues quickly.

Inspection outcome at Moraiya facility

The USFDA inspection at the Moraiya plant concluded with 5 observations issued to Zydus Lifesciences. The company has communicated its intent to address and resolve the observations promptly.

Company's stated response

Zydus Lifesciences indicated it plans to resolve the observations quickly. No further details regarding the nature of the individual observations or a specific resolution timeline were provided in the available information.

Regulatory disclosure details

The company disclosed the inspection conclusion pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The press release was signed by Dhaval N. Soni, Company Secretary and Compliance Officer.